Granato D, Blum S, Rössle C, Le Boucher J, Malnoë A, Dutot G
Nestlé Research Center, Nestec LTD, Vers-chez-les-Blanc, Lausanne, Switzerland.
JPEN J Parenter Enteral Nutr. 2000 Mar-Apr;24(2):113-8. doi: 10.1177/0148607100024002113.
Numerous studies suggest that immune function may be compromised by lipid emulsions rich in polyunsaturated fatty acids (PUFAs). In our study, we compared the effect of a new olive oil-based lipid emulsion (ClinOleic) containing a moderate level of PUFAs, with emulsions based on soybean oil (Intralipid or Ivelip), on immune functions of human cell in vitro.
Peripheral white blood cells were collected from healthy volunteers. Lymphocyte proliferation was evaluated by [3H]-thymidine incorporation after stimulation with either phytohemagglutinin (PHA) or antibodies against T-cell specific antigens. Lymphocytes subsets and T-cell activation markers (CD25 and HLA-DR) were measured by flow cytometry. The release of cytokines (interleukin [IL]-2, IL-1beta, and tumor necrosis factor-alpha [TNF-alpha]) was measured by enzyme-linked immunosorbent assay (ELISA), after lymphocytes or monocytes/macrophages stimulation with PHA or lipopolysaccharide (LPS).
A significant dose-dependent inhibition of thymidine incorporation was observed with Intralipid and Ivelip (incorporation down to 39.9% of control, p < .001) whereas ClinOleic showed no inhibitory effect. Activation antigen expression on both CD4+ and CD8+ T-cells tended to decrease with Intralipid (CD25: -53.4% on CD4+ and -57.4% on CD8+; HLA-DR: -61.5% on CD4+ and -58.5% on CD8+) but not with ClinOleic (from -2.9% for CD25 on CD4+ to 16.7% for HLA-DR on CD4+). Intralipid decreased significantly IL-2 production (-39.0%, p < .05) whereas ClinOleic had little effect (-13.0%, NS). Intralipid and ClinOleic tended to inhibit to a similar extent the release of pro-inflammatory cytokines (TNF-alpha: -21.5% and -34.8%, IL-1beta: -45.1% and -40.3%; respectively).
Our results suggest that an olive oil-based lipid emulsion could modulate immune response selectively, maintaining protective immunity and reducing inflammatory response. Olive oil may offer an immunologically neutral alternative to soybean oil for use in parenteral lipid emulsions.
大量研究表明,富含多不饱和脂肪酸(PUFAs)的脂质乳剂可能会损害免疫功能。在我们的研究中,我们比较了一种含有中等水平PUFAs的新型橄榄油基脂质乳剂(ClinOleic)与基于大豆油的乳剂(英脱利匹特或伊维力匹)对人细胞体外免疫功能的影响。
从健康志愿者中采集外周血白细胞。在用植物血凝素(PHA)或抗T细胞特异性抗原的抗体刺激后,通过[3H] - 胸腺嘧啶核苷掺入评估淋巴细胞增殖。通过流式细胞术测量淋巴细胞亚群和T细胞活化标志物(CD25和HLA - DR)。在用PHA或脂多糖(LPS)刺激淋巴细胞或单核细胞/巨噬细胞后,通过酶联免疫吸附测定(ELISA)测量细胞因子(白细胞介素[IL] - 2、IL - 1β和肿瘤坏死因子 - α [TNF - α])的释放。
观察到英脱利匹特和伊维力匹对胸腺嘧啶核苷掺入有显著的剂量依赖性抑制(掺入量降至对照的39.9%,p <.001),而ClinOleic没有抑制作用。英脱利匹特使CD4 +和CD8 + T细胞上的活化抗原表达趋于降低(CD25:CD4 +上降低53.4%,CD8 +上降低57.4%;HLA - DR:CD4 +上降低61.5%,CD8 +上降低58.5%),但ClinOleic没有(从CD4 +上CD25降低2.9%到CD4 +上HLA - DR升高16.7%)。英脱利匹特显著降低IL - 2的产生(-39.0%,p <.05),而ClinOleic影响较小(-13.0%,无统计学意义)。英脱利匹特和ClinOleic对促炎细胞因子释放的抑制程度趋于相似(TNF - α:分别为-21.5%和-34.8%,IL - 1β:分别为-45.1%和-40.3%)。
我们的结果表明,橄榄油基脂质乳剂可以选择性地调节免疫反应,维持保护性免疫并减少炎症反应。橄榄油可能为用于胃肠外脂质乳剂的大豆油提供一种免疫中性的替代品。